WADA prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== SELDI surface === The binding of proteins to the SELDI surface acts as a solid-phase chromatographic separation step, and as a result, the proteins attached to the surface are easier to analyze. The surface is composed primarily of materials with a variety of physico-chemical characteristics, metal ions, or anion or cation exchangers. Common surfaces include CM10 (weak cation exchange), H50 (hydrophobic surface, similar to C6-C12 reverse phase chromatography), IMAC30 (metal-binding surface), and Q10 (strong anion exchange). SELDI surfaces can also be modified to study DNA-protein binding, antibody-antigen assays, and receptor-ligand interactions.
In addition, a direct joining of ribose, a nucleobase, and phosphate to make a ribonucleotide (the building block of RNA) is not currently chemically feasible. Alternative prebiotic mechanisms have been proposed including cyanosulfidic prebiotic chemistries.
==== Immigration ==== Nearly eight million immigrants came to the U.S. from 2000 to 2005, more than in any other five-year period in the nation's history. Almost half entered illegally. In 2006, Bush urged Congress to allow more than twelve million illegal immigrants to work in the United States with the creation of a "temporary guest-worker program". Bush also urged Congress to provide additional funds for border security and committed to deploying 6,000 National Guard troops to the Mexico–United States border. From May to June 2007, Bush strongly supported the Comprehensive Immigration Reform Act of 2007, which was written by a bipartisan group of senators with the active participation of the Bush administration. The bill envisioned a legalization program for illegal immigrants, with an eventual path to citizenship; the establishment of a guest worker program; a series of border and worksite enforcement measures; a reform of the green card application process and the introduction of a point-based "merit" system for green cards; elimination of "chain migration" and of the Diversity Immigrant Visa; and other measures. Bush argued that the lack of legal status denies the protections of U.S. laws to millions of people who face dangers of poverty and exploitation, and penalizes employers despite a demand for immigrant labor. Bush contended that the proposed bill did not amount to amnesty. A heated public debate followed, which resulted in a substantial rift within the Republican Party; most conservatives opposed it because of its legalization or amnesty provisions.
== Constitutionality in the United States == In 2006, the Supreme Court ruled in Hill v. McDonough that death-row inmates in the United States could challenge the constitutionality of states' lethal injection procedures through a federal civil rights lawsuit. Since then, numerous death-row inmates have brought such challenges in the lower courts, claiming that lethal injection as practiced violates the ban on "cruel and unusual punishment" found in the Eighth Amendment to the United States Constitution. Lower courts evaluating these challenges have reached opposing conclusions. For example, courts have found that lethal injection as practiced in California, Florida, and Tennessee is unconstitutional. Other courts have found that lethal injection as practiced in Missouri, Arizona, and Oklahoma is constitutionally acceptable. As of 2014, California has nearly 750 prisoners condemned to death by lethal injection despite the moratorium imposed when, in 2006 a federal court found California's lethal injection procedures to be unconstitutional. A newer lethal injection facility has been constructed at San Quentin State Prison which cost over $800,000, but it has yet to be used because a state court found that the California Department of Corrections and Rehabilitation violated the California Administrative Procedure Act by attempting to prevent public oversight when new injection procedures were being created. On September 25, 2007, the United States Supreme Court agreed to hear a lethal-injection challenge arising from Kentucky, Baze v. Rees.
Sources: en.wikipedia.org
William DeGrado (born 12 September 1955) is a professor at the University of California, San Francisco, where he is the Toby Herfindal Presidential Professor of Entrepreneurship and Innovation in the Department of Pharmaceutical Chemistry. As an early pioneer of protein design, he coined the term de novo protein design. He is also active in discovery of small molecule drugs for a variety of human diseases. He is a member of the U.S. National Academy of Sciences (1999), American Academy of Arts & Sciences (1997) and National Academy of Inventors. He also is a scientific cofounder of Pliant therapeutics.
"You have no idea what the Tour de France is," Henri said. "It's a Calvary. Worse than that, because the road to the Cross has only 14 stations and ours has 15. We suffer from the start to the end. You want to know how we keep going? Here..." He pulled a phial from his bag. "That's cocaine, for our eyes. This is chloroform, for our gums." "This," Ville said, emptying his shoulder bag "is liniment to put warmth back into our knees." "And pills. Do you want to see pills? Have a look, here are the pills." Each pulled out three boxes. "The truth is," Francis said, "that we keep going on dynamite." Henri spoke of being as white as shrouds once the dirt of the day had been washed off, then of their bodies being drained by diarrhea, before continuing:
=== MSG === In 1996, the FDA commissioned the Federation of American Society for Experimental Biology (FASEB) to study the effects of MSG, who concluded that MSG is safe for most people. At the time, Ajinomoto also noted the possibility that asthma patients and carriers with symptoms of Chinese restaurant syndrome symptoms may be affected, but ultimately, the safety of this group was also confirmed by subsequent test results in the United States and Australia. In 2020, Ajinomoto along with other activists launched the #RedefineCRS campaign to combat the myth that MSG is harmful to people's health, which highlights both the underlying xenophobic biases against Asian cuisine and scientific evidence that the myth is false. The FDA Food Code 2022 removed MSG from the table of common chemical hazards and associated food and control measures in retail establishments. Low-sodium salt substitutes are considered to be formulations where sodium is reduced – usually by partial or full replacement of NaCl with other chloride and non-chloride salts such as KCl, magnesium chloride, calcium chloride or potassium lactate. Monosodium glutamate (MSG) was also considered a low-sodium salt substitute.
The British government took these defeats badly and with the sieges continuing was compelled to send two more divisions plus large numbers of colonial volunteers. By January 1900 this would become the largest force Britain had ever sent overseas, amounting to 180,000 men with further reinforcements being sought. While watching for these reinforcements, Buller made another bid to relieve Ladysmith by crossing the Tugela west of Colenso. Buller's subordinate, Major General Charles Warren, successfully crossed the river, but was faced with a fresh defensive position centred on a prominent hill known as Spion Kop. In the resulting Battle of Spion Kop, British troops captured the summit by surprise during the early hours of 24 January 1900, but as the fog lifted, they realised too late that they were overlooked by Boer gun emplacements on the surrounding hills. The rest of the day resulted in a disaster caused by poor communication between Buller and his commanders. Between them they issued contradictory orders, on the one hand ordering men off the hill, while other officers ordered fresh reinforcements to defend it. The result was 350 men killed and nearly 1,000 wounded and a retreat across the Tugela River into British territory. There were nearly 300 Boer casualties. Buller attacked Louis Botha again on 5 February at Vaal Krantz and was again defeated. Buller withdrew early when it appeared that the British would be isolated in an exposed bridgehead across the Tugela, for which he was nicknamed "Sir Reverse" by some of his officers.
Single-cell proteins (SCP) or microbial proteins refer to edible unicellular microorganisms. The biomass or protein extract from pure or mixed cultures of algae, yeast, filamentous fungi or bacteria may be used as an ingredient or a substitute for protein-rich foods, and is suitable for human consumption or as animal feeds. Industrial agriculture is marked by a high water footprint, high land use, biodiversity destruction, general environmental degradation and contributes to climate change by emission of a third of all greenhouse gases; production of SCP does not necessarily exhibit any of these serious drawbacks. As of today, SCP is commonly grown on agricultural waste products, and as such inherits the ecological footprint and water footprint of industrial agriculture. However, SCP may also be produced entirely independent of agricultural waste products through autotrophic growth. Thanks to the high diversity of microbial metabolism, autotrophic SCP provides several different modes of growth, versatile options of nutrients recycling, and a substantially increased efficiency compared to crops. A 2021 publication showed that photovoltaic-driven microbial protein production could use 10 times less land for an equivalent amount of protein compared to soybean cultivation. With the world population reaching 9 billion by 2050, there is strong evidence that agriculture will not be able to meet demand and that there is serious risk of food shortage.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.